PCT/GB 2004 / 0 0 2 8 6 6

INVESTOR IN PEOPLE

GB04/ 2866

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

RECD 22 JUL 2004
WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed Andrea Gerry

Dated 12 July 2004

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

tents Form 1/77

P[illegible]s Act 1977
([illegible]46)

The Patent Office

1/77

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

PATENT OFFICE
04 JUL 2003
RECEIVED BY HAND

1. Your reference 444.81507/000

05JUL03 E820445-2 D00027
P01/7700 0.00-0315783.1

2. Patent application number *(The Patent Office will fill in this part)* 04 JUL 2003 0315783.1

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

Norferm DA - 0315783.1
Vasabomen
N-4003 Stavanger
Norway

07836265004
Patents ADP number *(if you know it)*

If the applicant is a corporate body, give country/state of incorporation: Norway

4. Title of the invention: USE

5. Name of your agent *(if you have one)*

Frank B. Dehn & Co.

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

179 Queen Victoria Street
London
EC4V 4EL

Patents ADP number *(if you know it)* 166001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Yes

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	9
Claim(s)	2
Abstract	-
Drawing(s)	-

10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	-
Request for preliminary examination and search *(Patents Form 9/77)*	-
Request for substantive examination *(Patents Form 10/77)*	-
Any other documents *(please specify)*	-

11. I/We request the grant of a patent on the basis of this application.

Signature [signature] Date 4th July 2003
Frank B Dehn & Co

12. Name and daytime telephone number of person to contact in the United Kingdom

Julian Cockbain
020 7206 0600

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
b) *Write your answers in capital letters using black ink or you may type them.*
c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.*
d) *If you have answered 'Yes', Patents Form 7/77 will need to be filed.*
e) *Once you have filled in the form you must remember to sign and date it.*
f) *For details of the fee and ways to pay please contact the Patent Office.*

81507.621

Use

This invention relates to the use of microbial cells and extracts and derivatives thereof for the treatment of human or non-human vertebrate animal, especially mammalian, avian or piscine, subjects to modify lipid metabolization, in particular to reduce plasma cholesterol levels therein or to maintain low plasma cholesterol levels therein.

Overly high total plasma cholesterol levels in mammals are associated with increased risk of coronary heart disease. Those particularly at risk include the overweight, smokers, those with a poor diet (e.g. one rich in saturated fats), those who take inadequate exercise, and those suffering from stress. This is not a problem restricted to humans but is also one which occurs with pet animals and farmed animals.

For at risk individuals, as well as those tested and found to have unduly high plasma cholesterol levels, a variety of treatments have been prepared, e.g. changes in diet and habits, increased exercise, etc. However such treatments are not always easy to enforce and there remains a need for treatments which can be effective at reducing plasma cholesterol levels.

In WO 01/60974 and WO 03/016460 there is described a method by which microorganisms may be cultured, with the primary intention of producing a protein-containing material which could be used as a foodstuff or as an additive therefor.

We have now surprisingly found that lipids produced by microbes (e.g. bacteria, yeast or funghi, in particular bacteria) when used as a major or minor part of the lipid intake in an animal's diet, serve to reduce the animal's plasma cholesterol levels. Thus such microbial lipids may be used in a method of treatment to reduce plasma cholesterol, to maintain a reduced plasma

cholesterol level, or to reduce the ratio of LDL to HDL cholesterol.

Thus viewed from one aspect the invention provides the use of microbial lipids for the manufacture of a composition, e.g. a pharmaceutical, nutraceutical or foodstuff, for oral administration for use in the treatment of animal subjects to reduce plasma cholesterol, in particular LDL cholesterol, levels therein, or to reduce the ratio of LDL to HDL cholesterol in the plasma thereof.

The word animal as used herein is used to refer to humans and non-humans, particularly vertebrates, e.g. mammals, birds and fish, but also, less preferably shellfish. Use of the invention in relation to humans and other mammals as well as gallinaceous birds (e.g. domestic fowl) and farmed fish (e.g. salmon and trout) is particularly preferred. Use in relation to humans, non-human mammals and domestic fowl is especially preferred.

Viewed from a further aspect the invention provides a method of treatment of an animal subject to reduce plasma cholesterol levels therein, to maintain a reduced plasma cholesterol level therein or to reduce the ratio of LDL to HDL cholesterol in the plasma thereof, said method comprising orally administering to said subject, e.g. as part of its dietary intake, an effective amount of a microbial lipid.

By a microbial lipid is meant herein a lipid produced by a microbe, e.g. a bacteria, yeast or fungus. Such lipids will generally be produced so as to constitute part of the microbe's internal or external membranes. Typically such lipids comprise phospholipids, e.g. phosphatidylglycerols, phosphatidylethanolamines, phosphatidylcholines, and cardiolipins. In the case of bacteria, the preferred source of the microbial lipids used according to the invention, the lipids in the microbes are majoratively

phospholipids (i.e. the head group to which the fatty acid side chains are attached includes a phosphorus atom). The use of bacteria which have a high phospholipid content and in particular a high phosphatidylethanolamine content (relative to total lipid content, e.g. a phospholipid content of at least 30% wt., preferably a phosphatidylethanolamine content of at least 30% wt. relative to total lipid content) is especially preferred, e.g. Gram-negative bacteria and in particular bacteria having membranes for nutrient gas fixation, particularly methanotrophic bacteria, and especially methylococcus bacteria. The use of bacteria in which phospholipids, and especially phosphatidylethanolamines, constitute at least 60% wt of the total lipid contact is especially preferred.

Quite surprisingly such microbial phospholipids have a marked cholesterol reducing effect despite the fact that the fatty acid side chains are predominantly saturated or monounsaturated (i.e. they are fatty acids of a type which would be expected to increase plasma cholesterol).

Interestingly, plasma triacylglycerol levels may also be reduced by administration of microbial lipids in accordance with the present invention and in further aspects of the invention the reduction in triacylglycerols rather than or as well as an effect on cholesterol may be the aim of the claimed products or methods.

The fatty acid side chains in such lipids are generally C_{14} to C_{22} fatty acids, particularly C_{16} fatty acids and in a preferred embodiment these are predominantly (e.g. >80% wt.) saturated or monounsaturated fatty acids, especially $C_{16:0}$ and $C_{16:1}$ fatty acids. The microbial lipid used according to the invention preferably contains phosphatidylethanolamines as the major lipid constituent, e.g. at least 50% wt., more preferably at least 65% wt.

The microbial lipids used according to the invention may if desired be separated from the other components of the microbes before use, e.g. from proteins, nucleic acids, etc. However, since the microbial lipids may be used as part of the dietary intake of the animal, i.e. to meet part of its nutritional needs, such lipid separation is not essential since the other components may also contribute to the animal's nutritional needs.

In general, it is preferred that the microbial lipid be used in the form of a lipid extract from a microbial biomass, e.g. a culture, prepared for example as described in WO 01/60974 and WO 03/016460, the contents of which are hereby incorporated by reference. The homogenization step referred to in WO 01/60974 may be omitted and the biomass from the reactor may be subjected to a conventional lipid extraction technique, e.g. solvent extraction. Preferably such extraction will involve use of a polar organic solvent or solvent mixture, e.g. a mixture of an alcohol and a halocarbon, especially a methanol/chloroform mixture, particularly a 1:2 v/v methanol/chloroform mixture. Such an extraction process forms a further aspect of the present invention.

Microbial lipid extracts are themselves novel and form a further aspect of the invention. They are chemically distinct from plant derived lipids in terms of their fatty acid profile as they are substantially free from polyunsaturated fatty acids. As a result they have increased storage stability. Viewed from this aspect the invention thus provides a microbial lipid, preferably at least 80% wt. pure, especially at least 90% wt. pure, particularly at least 95% wt. pure, e.g. >99% wt. pure, and preferably in a quantity of at least 10g, especially at least 50g, more especially at least 100g.

Following extraction from the microbial biomass, the lipid extract may if desired be purified or

separated into lipid fractions (e.g. chromatographically). The phospholipid (-containing) fractions, and in particular the phosphatidylethanolamine (-containing) fractions, especially the fraction(s) containing phosphatidylethanolamines with $C_{16:0}$ and/or $C_{16:1}$ fatty acid side chains, are especially preferred for use according to the invention.

Viewed from a further aspect the invention provides a microbe-derived phospholipid, especially a phosphatidylethanolamine, and particularly a phosphatidylethanolamine with $C_{16:0}$ and/or $C_{16:1}$ fatty acid side chains, preferably at least 80% wt. pure, especially at least 90% wt. pure, particularly at least 95% wt. pure, e.g. >99% wt. pure, and preferably in a quantity of at least 10g, especially at least 50g, more especially at least 100g, e.g. for use in medicine.

Such microbial lipid extracts may be used as ingredients in foodstuffs, e.g. as a total or partial replacement for fats contained therein, or as an additional lipid component. Typical such foodstuffs include margarines and other spreads, mayonnaise and other salad dressings, yoghurts, creams (including non-dairy creams etc.), cheeses and cooking oils and fats. Such foodstuffs form a further aspect of the invention.

Alternatively, the microbially derived lipids may be administered in pharmaceutical or nutraceutical form, e.g. formulated as solutions, suspensions or emulsions, in capsules, etc. Conventional pharmaceutical carriers and excipients and conventional formulation techniques may be used. Where the product is in dosage unit form, the dose unit preferably contains 100 to 1500 mg, especially 300 to 700 mg, particularly 400 to 600 mg. Formulation in capsule form is especially preferred, e.g. using gelatin capsule cases. A daily dose would typically be 0.02 to 0.5 g/kg bodyweight, preferably 0.05 to 0.25 g/kg bodyweight.

Thus viewed from a further aspect the invention provides a foodstuff containing a microbial lipid extract (preferably providing at least 5% wt. of the total lipid content of the foodstuff, more preferably at least 10% wt, especially at least 25% wt.) and a further nutrient component, preferably of non-microbial origin.

Viewed from a still further aspect the invention also provides a pharmaceutical or nutraceutical composition comprising a microbial lipid extract together with a pharmaceutically acceptable carrier or excipient.

The animal recipient of the microbial lipids according to the invention will preferably be a mammal or bird found to have elevated plasma cholesterol levels or considered to be at risk of elevated plasma cholesterol levels, e.g. due to its weight, diet, habits or living conditions. Such animals include in particular humans; however the invention is also applicable to pet animals (e.g. dogs, cats, rabbits, guinea pigs, etc.) and to farm animals, (e.g. poultry (for example chickens, ducks, geese and turkeys), pigs, cows, goats and sheep). The microbial lipids preferably constitute from 1 to 99% wt. of the animal's dietary lipid intake, more especially 10 to 90% wt. particularly 20 to 80% wt., more particularly 30 to 70% wt. In general, it is preferred that the animal's diet includes further lipids of non-microbial origin, e.g. fish oils or plant oils, to ensure the necessary intake of polyunsaturated fatty acids and C_{18} fatty acids. Soy bean oil, rape seed oil, sunflower oil, maize oil, evening primrose oil and fish oils are especially preferred for use in this regard.

The use of the microbial lipids in the feed for food animals (e.g. chicken etc.) may also lower the cholesterol in the meat or eggs (avian eggs that is) that are produced from or by such animals for human consumption and such reduced cholesterol food products

provide a still further aspect of the present invention. Desirably the animal is fed the microbial lipids for a period of at least one week, preferably at least two weeks before the reduced cholesterol food product (e.g. meat or poultry eggs) is harvested.

The microbial lipids (or a microbe-based product such as a homogenizate etc.) may be administered alone; however more generally they will be formulated together with other nutritionally useful materials, e.g. meat, plant oils, fish oils, carbohydrates, flavours, vitamins, minerals, etc. Such a formulated product, since it has a therapeutically or prophylactically desired effect as well as a nutritional effect will generally be referred to as a functional food or as a nutraceutical composition. It is preferred that the microbial lipid constitute from 1 to 99% wt. of such a nutraceutical composition, more preferably 2 to 50% wt., especially 5 to 20% wt. If the nutraceutical composition, as is preferred, is in the form of a total feed (i.e. one which can supply the entire nutritional needs of the animal in terms of protein, carbohydrate and lipids), then it may be given to the animal at frequencies and in quantities routine for food for the size, age, gender and species of the animal in question.

The microbe source of the microbial lipid is preferably a bacterium or a mixture of bacteria cultured using methane as the carbon source, e.g. a *Methylococcus* species such as *M.capsulatus*, optionally together with *Ralstonia* (formerly *Alcaligenes*) and/or *Bacillus* and/or *Aneurinibacillus* species, such as *Ralstonia sp*, *Aneurinibacillus sp* and *B. agri*. Such strains are available from Norferm Danmark A/S, Stenhuggervej 22, DK-5230 Odense, Denmark. The microbes might be administered as live cultures; however more normally the microbe will be killed before administration (e.g. as a natural consequence of a homogenization or sterilization step, or before lipid extraction).

Quite surprisingly, if microbial lipids are extracted from the microbial biomass, the residual material (which contains proteins, nucleic acids, carbohydrates, etc) is of enhanced digestability relative to the biomass from which the lipid has not been extracted. The lipid-depleted biomass, and lipid-depleted biomass derivatives (e.g. homogenizates) their production by lipid extraction therefrom and their use in or as feedstuffs or feedstuff additives all form further aspects of the present invention.

The invention will now be described further with reference to the following non-limiting Example.

Example 1

Mink

The effects on plasma cholesterol in mink (*Mustela vison*) of three different high lipid diets (56E% from lipids, i.e. with lipids providing 56% of dietary energy input) with lipids extracted using methanol and chloroform from BPM (a bacterial biomass) replacing 0%, 17% and 67% of those in soybean oil, were studied. BPM is produced by culturing *Methylococcus capsulatus*, *Rastonia sp.*, *Brevibacillus agri* and *Aneurinibacillus sp.* using natural gas (99% methane), ammonia and mineral salts as described in WO 01/60974 and WO 03/016460. Phospholipids are the main lipid component in BPM, consisting mainly of phosphatidylethanolamines, together with some phosphatidylglycerols, with predominantly 16:0 and 16:1 fatty acids and no polyunsaturated fatty acids.

The 0%, 17% and 67% bacterial lipid diet compositions were as set out in Table 1 below.

Table 1

Ingredient	0%	17%	67%
Corn starch	62.9	62.9	62.9
Coalfish fillet	651.4	651.4	651.4
Soybean oil	91.4	61	15.3
Bacterial lipids	-	30.5	76.2
Sunflower oil	2.29	2.29	2.29
Vitamin/mineral mix (100 kCal/100g)	0.84	0.84	0.84
BHT (100 mg/kg)	0.08	0.08	0.08
Calcium phosphate	1.63	1.63	1.63
Calcium carbonate	1.85	1.85	1.85
Water	187.7	187.7	187.7

The figures in columns are in g/kg.

18 growing mink were fed one of the three diets during a 25-day period in a parallel group design. The mink had their main part of the plasma cholesterol in the HDL fraction. Total cholesterol, LDL cholesterol, HDL cholesterol, VLDL cholesterol and the LDL/HDL cholesterol ratio were significantly lower by 34.5%, 49.2%, 28.8%, 29.7%, and 26.8%, respectively, when the mink consumed diets with 67% lipids from BPM and 33% lipids from soybean oil as compared to diets containing 100% lipids from soybean oil.

These reductions are especially significant since soybean oil itself is known to have a plasma cholesterol lowering effect.

The plasma concentrations of triacylglycerols (i.e. triglycerides) were also measured and were lower by 31.0% when the mink consumed diets with 67% lipids from BPM and 33% lipids from soybean oil as compared to diets containing 100% lipids from soybean oil.

Claims

1. The use of microbial lipids for the manufacture of a composition for oral administration for use in the treatment of animal subjects to reduce plasma cholesterol levels therein or to reduce the ratio of LDL to HDL cholesterol in the plasma thereof.

2. A method of treatment of an animal subject to reduce plasma cholesterol levels therein, to maintain a reduced plasma cholesterol level therein, or to reduce the ratio of LDL to HDL cholesterol in the plasma thereof, said method comprising orally administering to said subject an effective amount of a microbial lipid.

3. Microbial lipid for use as a medicament.

4. Methylococcus lipid for use as a medicament.

5. A microbial lipid, preferably at least 80% wt. pure, and preferably in a quantity of at least 10g.

6. A microbe-derived phospholipid, especially a phosphatidylethanolamine, and particularly a phosphatidylethanolamine with $C_{16:0}$ and/or $C_{16:1}$ fatty acid side chains, preferably at least 80% wt. pure, and preferably in a quantity of at least 10g, e.g. for use in medicine.

7. A foodstuff containing a microbial lipid extract and a further nutrient component, preferably of non-microbial origin.

8. A pharmaceutical or nutraceutical composition comprising a microbial lipid extract together with a pharmaceutically acceptable carrier or excipient.

9. A food product harvested from an animal fed with a microbial lipid.

10. A product as claimed in claim 9 in the form of an avian egg.